Serum antibodies to heparan sulfate glycosaminoglycans in Guillain- Barre syndrome and other demyelinating polyneuropathies

Journal of Neuroimmunology

Volumn 91, Issue 1-2, 1998, Pages 204-209

  Pestronk, A ^a   Choksi, R ^a   Yee, W C ^a   Kornberg, A J ^b   Lopate, G ^a   Trotter, J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Antibodies; Demyelination; Glycosaminoglycans; Guillain Barre syndrome; Heparan sulfate; Humoral immunity; Myelin; Polyneuropathy; Proteoglycans

Indexed keywords

GLYCOSAMINOGLYCAN; PROTEOHEPARAN SULFATE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; DEMYELINATING DISEASE; ELECTRODIAGNOSIS; ENZYME SPECIFICITY; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; POLYNEUROPATHY; PRIORITY JOURNAL;

AUTOANTIBODIES; DEMYELINATING DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSAMINOGLYCANS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; POLYNEUROPATHIES; POLYRADICULONEUROPATHY;

EID: 0032476717     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00182-9     Document Type: Article

References (37)

1. Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27:1990;S21-S24. (Suppl.).
2. Asbury A.K., McKhann G.M. Changing views of Guillain-Barré syndrome. Ann. Neurol. 41:1997;287-288.
3. Bhavanandan, V.P., Davidson, E.A., 1992. Proteoglycans: structure, synthesis, function. In: Allen, H.J., Kisailus, E.C. (Eds.), Glycoconjugates: Composition, Structure, and Function. Marcel Dekker, New York, pp. 167-202.
4. Carey D.J., Todd M.S. A cytoskeleton-associated plasma membrane heparan sulfate proteoglycan in Schwann cells. J. Biol. Chem. 261:1986;7518-7525.
5. Carey D.J., Stahl R.C. Identification of a lipid-anchored heparan sulfate proteoglycan in Schwann cells. J. Cell Biol. 111:1990;2053-2062.
6. Chiba A., Kusunoki S., Shimizu T., Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller-Fisher syndrome. Ann. Neurol. 31:1992;677-679.
7. Cole G.J., Halfter W. Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect. Dev. Neurobiol. 3:1996;359-371.
8. Faaber P., Rijke T.P., van de Putte L.B., Capel P.J., Berden J.H. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J. Clin. Invest. 77:1986;1824-1830.
9. Feasby T.E., Gilbert J.J., Brown W.F., Bolton C.F., Gilbert J.J., Koopman W.J. An acute axonal form of Guillain-Barré polyneuropathy. Brain. 109:1986;1115-1126.
10. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). New Engl. J. Med. 255:1956;57-65.
11. Fredman P., Vedeler C.A., Nyland H., Aarli J.A., Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J. Neurol. 238:1991;75-79.
12. Gilburd B., Stein M., Tomer Y., Tanne D., Abramski O., Chapman Y., Ahiron A., Blank M., Shoenfeld Y. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barré syndrome: cross-reactive or pathogenic? Autoimmunity. 16:1993;23-27.
13. Hafer-Macko C.E., Sheikh K.A., Li C.Y., Ho T.W., Cornblath D.R., McKhann G.M., Asbury A.K., Griffin J.W. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 39:1996;625-635.
14. Hardingham T.E., Fosang A.J. Proteoglycans: many forms and many functions. FASEB J. 6:1992;861-870.
15. Hartung H.P., Pollard J.D., Harvey G.K., Toyka K.V. Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part I. Muscle Nerve. 18:1995;137-153.
16. Ilyas A.A., Willison H.J., Quarles R.H., Jungalwala F.B., Cornblath D.R., Trapp B.D., Griffin D.E., Griffin J.W., McKhann G.M. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann. Neurol. 23:1988;440-447.
17. Kornberg A.J., Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve. 17:1994;100-104.
18. Kornberg A.J., Pestronk A., Bieser K., Ho T.W., McKhann G.M., Wu H.S., Jiang Z. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann. Neurol. 35:1994;234-237.
19. Kornberg A.J., Pestronk A., Blume G.M., Lopate G., Yue J., Hahn A. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes. Neurology. 47:1996;1317-1320.
20. Kusunoki S., Chiba A., Kon K., Ando S., Arisawa K., Tate A., Kanazawa I. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann. Neurol. 35:1994;570-576.
21. Makino H., Gibbons J.T., Reddy M.K., Kanwar Y.S. Nephritogenicity of antibodies to proteoglycans of the glomerular basement membrane - I. J. Clin. Invest. 77:1986;142-156.
22. Margolis R.K., Margolis R.U. Nervous tissue proteoglycans. Experientia. 49:1993;429-446.
23. McKhann G.M., Cornblath D.R., Griffin J.W., Ho T.W., Li C.Y., Jiang Z., Wu H.S., Zhaori G., Liu Y., Jou L.P., Liu T.C., Gao C.Y., Mao J.Y., Blaser M.J., Mishu B., Asbury A.K. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol. 33:1993;333-342.
24. Mehta H., Orphe C., Todd M.S., Cornbrooks C.J., Carey D.J. Synthesis by Schwann cells of basal lamina and membrane-associated heparan sulfate proteoglycans. J. Cell Biol. 101:1985;660-666.
25. Obremski V.J., Bunge M.B. Addition of purified basal lamina molecules enables Schwann cell ensheathment of sympathetic neurites in culture. Dev. Biol. 168:1995;124-137.
26. Peng H.B., Ali A.A., Dai Z., Daggett D.F., Raulo E., Rauvala H. The role of heparin-binding growth-associated molecule (HB-GAM) in the postsynaptic induction in cultured muscle cells. J. Neurosci. 15:1995;3027-3038.
27. Pestronk A., Choksi R. Multifocal motor neuropathy: serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology. 49:1997;1272-1289.
28. Pestronk A., Li F., Bieser K., Choksi R., Whitton A., Kornberg A.J., Goldstein J.M., Yee W.C. Anti-MAG antibodies: major effects of antigen purity and antibody cross-reactivity on ELISA results and clinical correlation. Neurology. 44:1994;1131-1137.
29. Rostami A.M. Guillain-Barré syndrome: clinical and immunological aspects. Springer Semin. Immunopathol. 17:1995;29-42.
30. Shibata S., Sasaki T., Harpel P., Fillit H. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin. Immunol. Immunopathol. 70:1994;114-123.
31. Stipp C.S., Litwack E.D., Lander A.D. Cerebroglycan: an integral membrane heparan sulfate proteoglycan that is unique to the developing nervous system and expressed specifically during neuronal differentiation. J. Cell Biol. 124:1994;149-160.
32. Sudhalter J., Whitehouse L., Rusche J.R., Marchionni M.A., Mahanthappa N.K. Schwann cell heparan sulfate proteoglycans play a critical role in glial growth factor/neuregulin signaling. Glia. 17:1996;28-38.
33. Timpl R. Proteoglycans of basement membranes. EXS. 70:1994;123-144.
34. van den Berg L.H., Marrink J., de Jager A.E., de Jong H.J., van Imhoff G.W., Latov N., Sadiq S.A. Anti-GM1 antibodies in patients with Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 55:1992;8-11.
35. Vriesendorp F.J., Mishu B., Blaser M.J., Koski C.L. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann. Neurol. 34:1993;130-135.
36. Watanabe K., Yamada H., Yamaguchi Y. K-glypican: a novel GPI-anchored heparan sulfate proteoglycan that is highly expressed in developing brain and kidney. J. Cell Biol. 130:1995;1207-1218.
37. Willison H.J., Kennedy P.G. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J. Neuroimmunol. 46:1993;105-112.